Controversy on the "Role for interferon-gamma release assays in latent tuberculosis screening before TNF-α antagonist therapy" Reply to the letter by Mrozek et al.

Joint Bone Spine

Volumn 78, Issue 6, 2011, Pages 656-657

  Lioté, Huguette ^a  

^a HÔPITAL TENON   (France)

Author keywords

Guidelines; IGRA; Latent tuberculosis; Prophylaxis; TNF blockers; Tuberculosis

Indexed keywords

TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; HUMAN; IMMUNOTHERAPY; INTERFERON GAMMA RELEASE ASSAY; LETTER; PRACTICE GUIDELINE; PREDICTIVE VALUE; RHEUMATOID ARTHRITIS; SCREENING; SPONDYLOARTHROPATHY; TUBERCULOSIS;

EID: 84855961704     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2011.09.001     Document Type: Letter

References (11)

1. Lioté H., Lioté F. Role for interferon-gamma release assays in latent tuberculosis screening before TNF-α antagonist therapy. Joint Bone Spine 2011, 10.1016/j.jbspin.2010.12.001.
2. Mrozek N., Peirera B., Dubost J., et al. What screening for tuberculosis before biologics? Comments about the article entitled "Role for interferon gamma releasing essay in latent tuber losis screening before TNF-α antagonist therapy" by Lioté H, et al. Joint Bone Spine 2011, 10.1016/j.jbspin.2011.07.002.
3. Diel R., Loddenkemper R., Nienhaus A. Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a metaanalysis. Chest 2010, 137:952-968.
4. Ling D.I., Pai M., Davids V., et al. Are interferon-(gamma) release assays useful for active tuberculosis in a high-burden setting?. Eur Respir J 2011, 10.1183/09031936.00181610.
5. Herrmann J.L., Belloy M., Porcher R., et al. Temporal dynamics of interferon gamma responses in children evaluated for tuberculosis. PLoS One 2009, 4:e4130.
6. Dyrhol-Riise A.M., Gran G., Wentzel-Larsen T., et al. Diagnosis and follow-up of treatment of latent tuberculosis; the utility of the QuantiFERON-TB Gold In-tube assay in outpatients from a tuberculosis low-endemic country. BMC Infect Dis 2010, 10:57.
7. Ringshausen F.C., Nienhaus A., Schablon A., et al. Predictors of persistently positive Mycobacterium-tuberculosis-specific interferon-gamma responses in the serial testing of health care workers. BMC Infect Dis 2010, 10:220.
8. Martin J., Walsh C., Gibbs A., et al. Comparison of interferon (gamma) release assays and conventional screening tests before tumour necrosis factor (alpha) blockade in patients with inflammatory arthritis. Ann Rheum Dis 2010, 69:181-185.
9. Behar S.M., Shin D.S., Maier A., et al. Use of the T-SPOT. TB assay to detect latent tuberculosis infection among rheumatic disease patients on immunosuppressive therapy. J Rheumatol. 2009, 36:546-551.
10. Diel R., Loddenkemper R., Meywald-Walter K., et al. Comparative performance of tuberculin skin test. QuantiFERON-TB-Gold In Tube assay, and T-Spot. TB test in contact investigations for tuberculosis. Chest 2009, 135:1010-1018.
11. Qumseya B.J., Ananthakrishnan A.N., Skaros S., et al. QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States. Inflamm Bowel Dis 2011, 17:77-83.